<DOC>
	<DOCNO>NCT01156636</DOCNO>
	<brief_summary>Prevalence heart failure ( HF ) leave ventricular ( LV ) diastolic dysfunction preserve ejection fraction ( EF ) ( HFpEF ) increase . Prognosis worsen development pulmonary vasoconstriction hypertension ( PH ) right ventricular ( RV ) failure . The investigator aim modulate pulmonary vascular tone RV burden HFpEF due high blood pressure ( HBP ) , use phosphodiesterase-5 ( PDE5 ) inhibitor sildenafil .</brief_summary>
	<brief_title>Phosphodiesterase-5 ( PDE5 ) Inhibition Pulmonary Hypertension Diastolic Heart Failure</brief_title>
	<detailed_description>Heart failure ( HF ) preserve left ventricular ( LV ) ejection fraction ( EF ) ( HFpEF ) public health problem major topic clinical cardiology . Its prevalence , fact , increase outcome seem similar HF LV systolic dysfunction ( LVSD ) . Pulmonary hypertension ( PH ) HFpEF highly prevalent often severe , like LVSD ( 3 ) , predictor morbidity mortality ( 4 ) . Because thin wall distensibility , right ventricle ( RV ) much vulnerable excessive afterload preload . The pulmonary circulation central determinant RV afterload , increase impendance RV ejection , like occur LV dysfunction , easily result RV failure , tricuspid regurgitation , central venous pressure ( CVP ) rise . Development RV failure unanimously view predictor poor prognosis underlie mechanism extensively investigate . Because prevalence clinical significance PH secondary HF , attenuation pulmonary vascular tone RV hemodynamic burden suggest goal achieve HF therapy . Attempts endothelin receptor antagonist , prostacyclin analogue , basically unsuccessful . Experimental model human study , show HF nitric oxide ( NO ) - dependent pulmonary vasodilatation impair pulmonary vascular resistance elevation least part due pulmonary endothelial dysfunction , suggest therapeutic strategy agent increase NO activity , like nitrate phosphodiesterase - 5 ( PDE5 ) inhibitor ( 12-14 ) . The latter agent offer double advantage selectively dilate pulmonary vessel produce tachyphylaxis . In 1-year duration study , primary end-point probe whether pulmonary hemodynamics RV performance HFpEF PH may target PDE5 inhibition sildenafil .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>LVEF &gt; 50 % sinus rhythm stable clinical condition define change therapeutic regimen , hospitalization 6 month precede recruitment . pulmonary artery systolic pressure &gt; 40 mm Hg , Patients receive nitrate A history pulmonary disease Alternative cause PH cardiacrelated Renal failure ( creatinine &gt; 2mg/dL ) Anemia Pericardial disease Cardiac amyloidosis</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Diastolic Heart Failure</keyword>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>